4DMedical has received clearance from the U.S. Food and Drug Administration (FDA) for its IQ-UIP™ product, an advanced AI-driven lung diagnostic tool designed to revolutionize the diagnosis of Usual Interstitial Pneumonia (UIP), the hallmark radiological pattern for diagnosing Interstitial Pulmonary Fibrosis (IPF).
Clinical challenges of UIP and IPF
Usual Interstitial Pneumonia (UIP), often linked to Idiopathic Pulmonary Fibrosis (IPF), is a rare yet severe condition characterised by chronic inflammation and progressive lung fibrosis. The median survival post-diagnosis ranges from 1 to 2 years, and the condition affects approximately 140,000 individuals annually in the United States alone, with over 50,000 new cases diagnosed each year.